NO316944B1 - Humaninsulinderivater og farmasoytiske preparater for behandling av diabetes - Google Patents

Humaninsulinderivater og farmasoytiske preparater for behandling av diabetes Download PDF

Info

Publication number
NO316944B1
NO316944B1 NO19961070A NO961070A NO316944B1 NO 316944 B1 NO316944 B1 NO 316944B1 NO 19961070 A NO19961070 A NO 19961070A NO 961070 A NO961070 A NO 961070A NO 316944 B1 NO316944 B1 NO 316944B1
Authority
NO
Norway
Prior art keywords
human insulin
derivative according
xaa
des
insulin
Prior art date
Application number
NO19961070A
Other languages
English (en)
Norwegian (no)
Other versions
NO961070D0 (no
NO961070L (no
Inventor
Ib Jonassen
Jan Markussen
John Broberg Halstrom
Svend Havelund
Asser Sloth Andersen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26065125&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO316944(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DK104493A external-priority patent/DK104493D0/da
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO961070D0 publication Critical patent/NO961070D0/no
Publication of NO961070L publication Critical patent/NO961070L/no
Publication of NO316944B1 publication Critical patent/NO316944B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO19961070A 1993-09-17 1996-03-15 Humaninsulinderivater og farmasoytiske preparater for behandling av diabetes NO316944B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK104493A DK104493D0 (da) 1993-09-17 1993-09-17 Hidtil ukendte peptider
US19082994A 1994-02-02 1994-02-02
PCT/DK1994/000347 WO1995007931A1 (en) 1993-09-17 1994-09-16 Acylated insulin

Publications (3)

Publication Number Publication Date
NO961070D0 NO961070D0 (no) 1996-03-15
NO961070L NO961070L (no) 1996-05-15
NO316944B1 true NO316944B1 (no) 2004-07-05

Family

ID=26065125

Family Applications (3)

Application Number Title Priority Date Filing Date
NO19961070A NO316944B1 (no) 1993-09-17 1996-03-15 Humaninsulinderivater og farmasoytiske preparater for behandling av diabetes
NO2004006C NO2004006I1 (no) 1993-09-17 2004-09-27 Insulin detemir
NO2017041C NO2017041I2 (no) 1993-09-17 2017-08-01 Insulin detemir

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO2004006C NO2004006I1 (no) 1993-09-17 2004-09-27 Insulin detemir
NO2017041C NO2017041I2 (no) 1993-09-17 2017-08-01 Insulin detemir

Country Status (30)

Country Link
US (1) US5750497A (cs)
EP (2) EP1132404A3 (cs)
JP (3) JP3014764B2 (cs)
KR (1) KR100310122B1 (cs)
CN (1) CN1056618C (cs)
AT (1) ATE204882T1 (cs)
AU (2) AU682061B2 (cs)
BG (1) BG61611B1 (cs)
BR (1) BR9407508A (cs)
CA (1) CA2171424C (cs)
CZ (1) CZ287945B6 (cs)
DE (2) DE122004000035I2 (cs)
DK (1) DK0792290T3 (cs)
ES (1) ES2163451T3 (cs)
FI (1) FI117055B (cs)
FR (1) FR04C0020I2 (cs)
HU (1) HU217684B (cs)
IL (1) IL110977A (cs)
LU (1) LU91101I2 (cs)
NL (1) NL300160I2 (cs)
NO (3) NO316944B1 (cs)
NZ (1) NZ273285A (cs)
PL (1) PL178466B1 (cs)
PT (1) PT792290E (cs)
RO (1) RO112873B1 (cs)
RU (1) RU2164520C2 (cs)
SI (1) SI0792290T1 (cs)
SK (1) SK282495B6 (cs)
UA (1) UA45321C2 (cs)
WO (1) WO1995007931A1 (cs)

Families Citing this family (193)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9316895D0 (en) * 1993-08-13 1993-09-29 Guy S And St Thomas Hospitals Hepatoselective insulin analogues
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US5474978A (en) * 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5504188A (en) * 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
DE4437604A1 (de) * 1994-10-21 1996-04-25 Basf Ag Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung
US5646242A (en) * 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
DE69629210T2 (de) * 1995-03-17 2004-04-22 Novo Nordisk A/S Insulinabkömmlinge
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
US20010041786A1 (en) * 1995-06-07 2001-11-15 Mark L. Brader Stabilized acylated insulin formulations
GB9513967D0 (en) * 1995-07-08 1995-09-06 Univ Leicester Insulin
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
JP4404380B2 (ja) * 1996-06-20 2010-01-27 ノボ ノルディスク アクティーゼルスカブ ＮａＣｌ含有インスリン製剤
WO1998002460A1 (en) * 1996-07-11 1998-01-22 Novo Nordisk A/S Selective acylation method
US5905140A (en) * 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
DK0821006T3 (da) * 1996-07-26 2004-08-16 Aventis Pharma Gmbh Insulinderivater med öget zinkbinding
US20020025933A1 (en) * 1996-08-30 2002-02-28 Knudsen Liselotte Bjerre GLP-2 derivatives
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
HUP0000547A3 (en) * 1997-03-20 2002-11-28 Novo Nordisk As Zinc free insulin crystals for use in pulmonary compositions
US6310038B1 (en) 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
US6043214A (en) * 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
HUP0004096A3 (en) * 1997-10-24 2001-12-28 Novo Nordisk As Aggregates of human insulin derivatives and pharmaceutical compositions comprising thereof
US6451762B1 (en) 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
EP0911035A3 (en) * 1997-10-24 2002-08-21 Eli Lilly And Company Insoluble insulin compositions
ID24890A (id) * 1997-10-24 2000-08-31 Lilly Co Eli Komposisi-komposisi insulin yang tidak dapat larut
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
ZA989744B (en) * 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
EP1396272A1 (en) * 1997-12-23 2004-03-10 Eli Lilly & Company Insoluble Insulin Compositions for Controlling Blood Glucose
CO4970787A1 (es) 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
WO1999034821A1 (en) * 1998-01-09 1999-07-15 Novo Nordisk A/S Stabilised insulin compositions
EP1060192A2 (en) * 1998-02-27 2000-12-20 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
DE19825447A1 (de) * 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh Neue Insulinanaloga mit erhöhter Zinkbildung
CA2334859A1 (en) * 1998-06-12 1999-12-23 Kings College London Insulin analogue
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
EP1265630B1 (en) 2000-03-24 2006-06-07 Genentech, Inc. Use of insulin for the treatment of cartilagenous disorders
AU2001254621A1 (en) * 2000-05-05 2001-11-20 K.U. Leuven R And D Critical illness neuropathy
US7316999B2 (en) 2000-06-02 2008-01-08 Novo Nordisk A/S Glucose dependent release of insulin from glucose sensing insulin derivatives
WO2002004515A1 (en) * 2000-07-10 2002-01-17 Btg International Limited Insulin derivatives and synthesis thereof
US20030054015A1 (en) * 2000-12-25 2003-03-20 Shinichiro Haze Sympathetic-activating perfume composition
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
EP1698636A1 (en) * 2001-05-02 2006-09-06 Novo Nordisk A/S Preparation of derivatized peptides from bile acids
US6653492B2 (en) 2001-05-02 2003-11-25 Novo Nordick A/S Preparation of bile acids
US7713932B2 (en) * 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
JP4721212B2 (ja) * 2001-07-05 2011-07-13 株式会社新日本科学 インスリンの経鼻投与用組成物
US7595172B2 (en) 2001-07-24 2009-09-29 Novo Nordisk A/S Method for making acylated polypeptides
JP2005508895A (ja) 2001-08-28 2005-04-07 イーライ・リリー・アンド・カンパニー Ｇｌｐ−１および基礎インスリンの予備混合物
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US6913903B2 (en) * 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
DK1430082T3 (da) 2001-09-07 2010-01-18 Biocon Ltd Fremgangsmåde til syntese af insulinpolypeptid-oligomer-konjugater og proinsulinpolypeptid-oligomerkonjugater samt fremgangsmåde til syntese deraf
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
JP4563675B2 (ja) 2001-10-12 2010-10-13 ハイ・ポイント・ファーマスーティカルズ、エルエルシー 置換ピペリジン類、およびヒスタミンｈ３受容体関連疾患の治療のためのその使用
MXPA04003569A (es) 2001-10-19 2004-07-23 Lilly Co Eli Mezclas bifasicas de glp-1 e insulina.
DE60236014D1 (de) 2001-11-19 2010-05-27 Novo Nordisk As Verfahren zur herstellung von insulinverbindungen
GB0206792D0 (en) 2002-03-22 2002-05-01 Leuven K U Res & Dev Normoglycemia
ATE496064T1 (de) * 2002-05-07 2011-02-15 Novo Nordisk As Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
WO2003105768A2 (en) 2002-06-13 2003-12-24 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
US20040038864A1 (en) * 2002-06-27 2004-02-26 Per Balschmidt Use of dimethyl sulfone as isotonicity agent
EP1546090B1 (en) * 2002-09-25 2009-06-24 Novo Nordisk A/S Method for producing acylated peptides
US7273921B2 (en) 2002-09-25 2007-09-25 Novo Nordisk A/S Method for producing acylated peptides
WO2004035624A2 (en) 2002-10-14 2004-04-29 Novo Nordisk A/S Glucagon - like peptide - 2 variants
US20040138099A1 (en) * 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
WO2004085472A1 (en) * 2003-03-27 2004-10-07 Novo Nordisk A/S Method for making human insulin precursors and human insulin
ATE482747T1 (de) 2003-04-11 2010-10-15 High Point Pharmaceuticals Llc Neue amide derivate und deren pharmazeutische verwendungen
WO2004096266A1 (en) * 2003-05-02 2004-11-11 Novo Nordisk A/S Improved physical stability of insulin formulations
EP2301749A1 (en) 2003-06-27 2011-03-30 Novo Nordisk A/S High moisture barrier container for medical liquid compositions
JP4463814B2 (ja) 2003-08-05 2010-05-19 ノボ ノルディスク アクティーゼルスカブ 新規のインスリン誘導体
SI2107069T1 (sl) 2003-08-05 2013-04-30 Novo Nordisk A/S Novi inzulinski derivati
WO2005047508A1 (en) 2003-11-14 2005-05-26 Novo Nordisk A/S Processes for making acylated insulin
AU2004290862B2 (en) 2003-11-20 2010-06-03 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
AU2004295023A1 (en) 2003-12-03 2005-06-16 Novo Nordisk A/S Single-chain insulin
ATE483580T1 (de) 2003-12-22 2010-10-15 Novo Nordisk As Durchsichtiger, flexibler, undurchlässiger kunststoffbehälter zur lagerung von pharmazeutischen flüssigkeiten
ATE550041T1 (de) 2004-01-21 2012-04-15 Novo Nordisk Healthcare Ag Transglutaminase-vermittelte konjugation von peptiden
JP5022213B2 (ja) * 2004-03-12 2012-09-12 バイオデル， インコーポレイテッド 迅速に作用する薬物送達組成物
WO2006008238A1 (en) * 2004-07-16 2006-01-26 Novo Nordisk A/S Method for selective acylation
PL2626368T3 (pl) 2004-07-19 2017-06-30 Biocon Limited Koniugaty insulina-oligomer, ich formulacje i zastosowania
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
WO2006082205A1 (en) * 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
EP2256130B1 (en) 2005-02-02 2013-09-25 Novo Nordisk A/S Novel insulin derivatives
EP1888118B1 (en) 2005-05-25 2016-08-17 Novo Nordisk A/S Polypeptide formulations stabilized with ethylenediamine
EP1888117A1 (en) * 2005-05-25 2008-02-20 Novo Nordisk A/S Stabilized polypeptide formulations
WO2006125765A2 (en) * 2005-05-26 2006-11-30 Novo Nordisk A/S Acylated insulin with high purity
MX2007015675A (es) 2005-07-04 2008-02-20 Novo Nordisk As Antagonistas del receptor de histamina h3.
EP1910317B1 (en) 2005-07-20 2013-07-03 Eli Lilly And Company 1-amino linked compounds
CN101243190B (zh) 2005-08-16 2015-05-13 诺沃-诺迪斯克有限公司 制备成熟胰岛素多肽的方法
US7741281B2 (en) * 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2007123581A1 (en) 2005-11-17 2007-11-01 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
ATE519780T1 (de) * 2005-12-28 2011-08-15 Novo Nordisk As Ein acyliertes insulin und zink enthaltende zusammensetzungen und verfahren zur herstellung dieser zusammensetzungen
AU2007207618B2 (en) * 2006-01-18 2011-03-24 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical compositions with enhanced stability
WO2007096431A1 (en) * 2006-02-27 2007-08-30 Novo Nordisk A/S Insulin derivatives
US20090069215A1 (en) * 2006-03-13 2009-03-12 Novo Nordisk A/S Acylated Single Chain Insulin
EP1996224B1 (en) 2006-03-15 2012-11-07 Novo Nordisk A/S Mixtures of amylin and insulin
US8394842B2 (en) 2006-03-28 2013-03-12 High Point Pharmaceuticals, Llc Benzothiazoles having histamine H3 receptor activity
ES2378574T3 (es) 2006-04-24 2012-04-16 Eli Lilly & Company Pirrolidinonas ciclohexilo substituidas como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1
AU2007247109B2 (en) 2006-05-09 2012-03-15 Novo Nordisk A/S Insulin derivative
CN101437849B (zh) * 2006-05-09 2015-09-30 诺沃-诺迪斯克有限公司 胰岛素衍生物
US8796205B2 (en) 2006-05-09 2014-08-05 Novo Nordisk A/S Insulin derivative
US7714025B2 (en) * 2006-05-10 2010-05-11 Arizona Biomedical Research Commission Modified chalcone compounds as antimitotic agents
BRPI0711370A2 (pt) 2006-05-29 2011-11-01 High Point Pharmaceuticals Llc 3-(1,3-benzodioxol-5-il)-6-(4-ciclopropilpiperazin-1-il)pi ridazina e seus sais e solvatos e seu uso como antagonista receptor h3 de histamina
KR20140109509A (ko) 2006-07-11 2014-09-15 큐피에스 엘엘씨 펩타이드의 지속 방출 전달을 위한 의약 조성물
EP2049149B1 (en) 2006-07-31 2015-04-15 Novo Nordisk A/S Pegylated extended insulins
DK2074141T3 (en) 2006-09-22 2016-11-28 Novo Nordisk As The protease resistant insulin analogues.
US8518668B2 (en) 2006-09-27 2013-08-27 Novo Nordisk A/S Method for making maturated insulin polypeptides in a fungal cell
WO2008049711A1 (en) * 2006-10-27 2008-05-02 Novo Nordisk A/S Peptide extended insulins
JP5496082B2 (ja) 2007-04-30 2014-05-21 ノボ・ノルデイスク・エー／エス タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
WO2008145730A1 (en) 2007-06-01 2008-12-04 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
US20110144010A1 (en) 2007-06-01 2011-06-16 Novo Nordisk A/S Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
ES2558930T3 (es) 2007-08-13 2016-02-09 Novo Nordisk A/S Análogos de la insulina de acción rápida
ES2664822T3 (es) * 2007-10-16 2018-04-23 Biocon Limited Una composición farmacéutica sólida administrable por vía oral y un proceso de la misma
WO2009060071A1 (en) * 2007-11-08 2009-05-14 Novo Nordisk A/S Insulin derivative
EP2058330A1 (en) * 2007-11-08 2009-05-13 Novo Nordisk A/S Insulin derivative
MX2010005245A (es) 2007-11-16 2010-06-01 Novo Nordisk As Composiciones farmaceuticas que comprenden peptidos glp-1 o exendin-4 y un peptido de insulina basal.
CA2711561A1 (en) * 2008-01-04 2009-07-16 Biodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
CN101970477B (zh) 2008-03-14 2014-12-31 诺沃-诺迪斯克有限公司 蛋白酶稳定的胰岛素类似物
EP2910569B1 (en) 2008-03-18 2016-10-05 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
MX2011001408A (es) 2008-08-07 2011-05-02 Biocon Ltd Proceso para la preparacion de compuestos de insulina.
EP2352513B1 (en) 2008-10-30 2016-09-14 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
EP2362730A4 (en) 2008-11-21 2012-08-29 High Point Pharmaceuticals Llc Adamantyl BENZAMIDE CONNECTIONS
US8940690B2 (en) 2009-01-28 2015-01-27 National Institutes Of Health (Nih) Synthetic conjugates and uses thereof
CA2750262C (en) * 2009-01-28 2016-08-09 Smartcells, Inc. Conjugate based systems for controlled drug delivery
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
CA2754950A1 (en) 2009-03-20 2010-09-23 Smartcells, Inc. Terminally-functionalized conjugates and uses thereof
WO2010140148A1 (en) 2009-06-01 2010-12-09 Yeda Research And Development Co . Ltd Prodrugs containing albumin binding probe
WO2011064316A2 (en) 2009-11-25 2011-06-03 Paolo Botti Mucosal delivery of peptides
EP2460527A1 (en) 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
US9981017B2 (en) 2010-04-02 2018-05-29 Hanmi Science Co., Ltd. Insulin conjugate using an immunoglobulin fragment
AR081066A1 (es) * 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
UY33326A (es) 2010-04-14 2011-12-01 Sanofi Aventis Conjugados de insulina-sirna
WO2011141407A1 (en) * 2010-05-10 2011-11-17 Novo Nordisk A/S Process for the preparation of insulin-zinc complexes
CN103154024A (zh) * 2010-10-15 2013-06-12 诺沃—诺迪斯克有限公司 新型n末端修饰的胰岛素衍生物
RU2013123515A (ru) 2010-10-27 2014-12-10 Ново Нордиск А/С Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами
MX345608B (es) 2010-12-22 2017-02-07 Baxalta Inc Materiales y metodos para conjugar un derivado de acido graso soluble en agua a una proteina.
PH12013501495A1 (en) 2011-01-20 2013-09-16 Zealand Pharma As Combination of acylated glucagon analogues with insulin analogues
US10130684B2 (en) 2011-02-03 2018-11-20 Pharmedica Ltd. Oral dissolving films for insulin administration, for treating diabetes
WO2012140647A2 (en) 2011-04-11 2012-10-18 Yeda Research And Development Co. Ltd Albumin binding probes and drug conjugates thereof
EP2548570A1 (en) 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
CN102504022A (zh) * 2011-11-30 2012-06-20 苏州元基生物技术有限公司 含有保护赖氨酸的胰岛素原及使用其制备胰岛素的方法
RU2014127270A (ru) 2011-12-15 2016-02-10 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Аналог человеческого инсулина и его ацилированное производное
BR112014025132A2 (pt) 2012-04-11 2017-07-11 Novo Nordisk As formulações de insulina
BR112014026442A8 (pt) 2012-05-01 2018-01-16 Novo Nordisk As combinação para alcançar o controle glicêmico, seu uso, e composição farmacêutica.
JP6735561B2 (ja) 2012-12-03 2020-08-05 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｏ−グリコシル化カルボキシ末端部分（ｃｔｐ）ペプチド系のインスリンおよびインスリン類似体
WO2014177623A1 (en) 2013-04-30 2014-11-06 Novo Nordisk A/S Novel administration regime
CA2924109A1 (en) 2013-09-13 2015-03-19 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
CA2926701A1 (en) 2013-10-07 2015-04-16 Novo Nordisk A/S Novel derivative of an insulin analogue
WO2015095406A1 (en) 2013-12-18 2015-06-25 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
US9656017B2 (en) 2014-06-20 2017-05-23 Howard E. Greene Infusion delivery devices and methods
WO2016205488A1 (en) 2015-06-17 2016-12-22 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
KR20180038049A (ko) 2015-08-25 2018-04-13 노보 노르디스크 에이/에스 신규한 인슐린 유도체 및 그것의 의학적 사용
CN114478747B (zh) * 2016-08-02 2024-06-14 江苏恒瑞医药股份有限公司 一种人胰岛素或其类似物的酰化衍生物
EP3329930A1 (en) 2016-12-05 2018-06-06 Nuritas Limited Pharmaceuctical compositions
MX388822B (es) 2016-12-05 2025-03-20 Nuritas Ltd Composiciones que comprenden peptido wkdeagkplvk.
SI3554534T1 (sl) 2016-12-16 2021-09-30 Novo Nordisk A/S Farmacevtski sestavki, ki vsebujejo inzulin
RS65380B1 (sr) 2017-08-24 2024-04-30 Novo Nordisk As Glp-1 kompozicije i njihova upotreba
CN111406073A (zh) * 2017-09-29 2020-07-10 韩美药品株式会社 具有提高功效的持久性蛋白质缀合物
EP3740212A4 (en) 2017-12-18 2021-10-27 Merck Sharp & Dohme Corp. CONJUGATE-BASED SYSTEMS FOR CONTROLLED INSULIN DELIVERY
US11820805B2 (en) 2017-12-18 2023-11-21 Merck Sharp & Dohme Llc Conjugate based systems for controlled insulin delivery
JP2021513330A (ja) 2018-02-09 2021-05-27 江蘇恒瑞医薬股▲ふん▼有限公司 ヒトインスリンアナログのコドン最適化前駆体遺伝子およびシグナルペプチド遺伝子
US20210198311A1 (en) 2018-05-24 2021-07-01 Jiangsu Hengrui Medicine Co., Ltd. Method for preparing precursor of recombinant human insulin or analogue thereof
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
KR102666154B1 (ko) 2018-08-08 2024-05-20 주식회사 대웅제약 지속형 인슐린 아날로그 및 그 복합체
TW202039437A (zh) 2018-12-11 2020-11-01 法商賽諾菲公司 肽黏合劑
KR20200080747A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법
KR20200080748A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법
CN111909255A (zh) * 2019-05-10 2020-11-10 宁波鲲鹏生物科技有限公司 胰岛素衍生物及其制备方法
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation
TW202434620A (zh) 2019-07-31 2024-09-01 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
RS65822B1 (sr) 2019-12-11 2024-09-30 Novo Nordisk As Novi insulinski analozi i njihova upotreba
US20240239859A1 (en) 2019-12-30 2024-07-18 Gan & Lee Pharmaceuticals Co., Ltd. Long-Acting GLP-1 Compound
CN118420743A (zh) 2019-12-30 2024-08-02 甘李药业股份有限公司 胰岛素衍生物
IL294520A (en) 2020-02-18 2022-09-01 Novo Nordisk As Pharmaceutical formulations
CR20220555A (es) 2020-03-31 2023-01-23 Protomer Tech Inc Conjugados para reactividad selectiva a dioles vecinales
KR20230110505A (ko) 2020-11-19 2023-07-24 프로토머 테크놀로지스 인크. 방향족 붕소-함유 화합물 및 인슐린 유사체
CN117794946A (zh) 2021-06-09 2024-03-29 斯克利普斯研究所 长效双重gip/glp-1肽缀合物及使用方法
EP4299057A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4180060A1 (en) 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
US20250000948A1 (en) 2021-11-15 2025-01-02 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
WO2023143458A1 (zh) 2022-01-28 2023-08-03 甘李药业股份有限公司 酰化胰岛素
EP4299071A1 (en) 2022-07-01 2024-01-03 Adocia Compositions comprising a peptide or a protein and an acylated amino acid
WO2024051787A1 (zh) * 2022-09-09 2024-03-14 北京惠之衡生物科技有限公司 一种长效酰化胰岛素衍生物及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3823125A (en) * 1969-10-14 1974-07-09 American Home Prod N-aminoacyl-substituted insulins
US3950517A (en) * 1970-05-08 1976-04-13 National Research Development Corporation Insulin derivatives
GB1381274A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
GB1381273A (en) * 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3907763A (en) * 1972-03-01 1975-09-23 Bayer Ag Insulin derivatives crosslinked by a dicarboxylic acid moiety
DK319780A (da) * 1980-07-24 1982-01-25 Forenede Bryggerier As Fremgangsmaade til enzymatisk udskiftning af b-30 aminosyren i insuliner
NL8201650A (nl) * 1982-04-21 1983-11-16 Akzo Nv Semisynthetische bereiding van humane insuline.
IL68769A (en) * 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
US5008241A (en) * 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
JPH01254699A (ja) * 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
DK45590D0 (cs) * 1990-02-21 1990-02-21 Novo Nordisk As
DK155690D0 (da) * 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
WO1992001476A1 (en) * 1990-07-26 1992-02-06 University Of Iowa Research Foundation Novel drug delivery systems for proteins and peptides using albumin as a carrier molecule
US5336782A (en) * 1991-04-24 1994-08-09 Kuraray Co., Ltd. Long chain carboxylic acid imide ester

Also Published As

Publication number Publication date
JP3014764B2 (ja) 2000-02-28
SK282495B6 (sk) 2002-02-05
NO2004006I1 (no) 2004-10-11
FR04C0020I2 (fr) 2005-05-27
CA2171424C (en) 2002-06-04
JP2002308899A (ja) 2002-10-23
JP3917333B2 (ja) 2007-05-23
UA45321C2 (uk) 2002-04-15
RU2164520C2 (ru) 2001-03-27
FI961220A0 (fi) 1996-03-15
US5750497A (en) 1998-05-12
KR100310122B1 (ko) 2002-04-24
AU7652094A (en) 1995-04-03
AU4846197A (en) 1998-02-19
BG61611B1 (bg) 1998-01-30
FI117055B (fi) 2006-05-31
EP1132404A3 (en) 2002-03-27
NL300160I2 (nl) 2005-07-01
JPH09502867A (ja) 1997-03-25
CZ78996A3 (en) 1996-10-16
LU91101I2 (en) 2004-11-08
ES2163451T3 (es) 2002-02-01
NO961070D0 (no) 1996-03-15
JP4060583B2 (ja) 2008-03-12
PL313444A1 (en) 1996-07-08
HU9600676D0 (en) 1996-05-28
FR04C0020I1 (cs) 2004-10-29
EP1132404A2 (en) 2001-09-12
NO2004006I2 (cs) 2008-02-04
NO2017041I1 (no) 2017-08-01
BG100420A (bg) 1996-12-31
DE122004000035I2 (de) 2009-08-06
DK0792290T3 (da) 2001-10-01
IL110977A (en) 2000-06-29
ATE204882T1 (de) 2001-09-15
BR9407508A (pt) 1997-01-07
DE69428134D1 (de) 2001-10-04
SK32496A3 (en) 1996-11-06
CN1056618C (zh) 2000-09-20
NL300160I1 (nl) 2004-12-01
HUT75991A (en) 1997-05-28
DE69428134T2 (de) 2002-05-02
HU217684B (hu) 2000-03-28
IL110977A0 (en) 1994-11-28
EP0792290A1 (en) 1997-09-03
KR960704925A (ko) 1996-10-09
PT792290E (pt) 2002-01-30
AU682061B2 (en) 1997-09-18
PL178466B1 (pl) 2000-05-31
NZ273285A (en) 1997-10-24
CN1133598A (zh) 1996-10-16
DE122004000035I1 (de) 2005-02-24
FI961220L (fi) 1996-05-14
CZ287945B6 (cs) 2001-03-14
RO112873B1 (ro) 1998-01-30
CA2171424A1 (en) 1995-03-23
SI0792290T1 (en) 2001-12-31
JP2000060556A (ja) 2000-02-29
NO961070L (no) 1996-05-15
WO1995007931A1 (en) 1995-03-23
NO2017041I2 (no) 2018-11-19
EP0792290B1 (en) 2001-08-29

Similar Documents

Publication Publication Date Title
NO316944B1 (no) Humaninsulinderivater og farmasoytiske preparater for behandling av diabetes
US6869930B1 (en) Acylated insulin
US6011007A (en) Acylated insulin
US7229964B2 (en) Insulin derivatives
JP3872105B2 (ja) インスリン誘導体
JP5697831B2 (ja) 単鎖インシュリン
AU745983B2 (en) Acylated insulin

Legal Events

Date Code Title Description
SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: LEVENMIR; NAT. REG. NO/DATE: EU/1/04/278/001-009/NO 20040614

Spc suppl protection certif: 2004006

Filing date: 20040927

Extension date: 20181110

ERR Erratum

Free format text: I PATENTTIDENDE NR.06/08 BLE DET I KUNNGJORINGEN AV MEDDELT SUPPLERENDE BESKYTTELSESSERTIFIKAT FOR LEGEMIDLER NR. 2004006, OPPGITT FEIL FORSTE MARKEDSFORINGSTILLATELSE I NORGE VED STATENS LEGEMIDDELVERK, RIKTIG SKAL VAERE:EU/1/04/278/001-009/NO, 20040601

MK1K Patent expired
SPCE Application to extend a supplementary protection certificate (spc)

Free format text: PRODUCT NAME: INSULIN DETEMIR; NAT. REG. NO/DATE: NO, EU/1/04/278/001-009 20040601; FIRST REG. NO/DATE: CH, 56370,71,72 20031110

Spc suppl protection certif: 2017041

Filing date: 20170801

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: INSULIN DETEMIR; NAT. REG. NO/DATE: NO, EU/1/04/278/001-009 20040601; FIRST REG. NO/DATE: CH, 56370,71,72 20031110

Spc suppl protection certif: 2017041

Filing date: 20170801

Extension date: 20190510

SPCX Expiry of an spc

Spc suppl protection certif: 2004006

SPCX Expiry of an spc

Spc suppl protection certif: 2017041